These Rare Genetic Diseases Are Finally Getting Attention From Drug Companies
Inverse,
The seizures started when Samantha Gundel was just four months old. By her first birthday, she was taking a cocktail of three…
Hope for Haploinsufficiency Diseases
Discover Magazine,
The seizures started when Samantha Gundel was just four months old. By her first birthday, she was taking a cocktail of three…
New therapies offer hope for patients with rare genetic conditions
Popular Science,
This article originally appeared in Knowable Magazine. The seizures started when Samantha Gundel was just four months old.
Hope for haploinsufficiency diseases
Yahoo! News,
The seizures started when Samantha Gundel was just four months old. By her first birthday, she was taking a cocktail of three…
Notable papers in autism research, 2020 | Spectrum | Autism Research News
Spectrum News,
Better outcomes: Boosting expression of a sodium channel in a mouse model of Dravet syndrome lowers a mouse's chances of having…
STOKE THERAPEUTICS : Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome
MarketScreener,
Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet…
Investigational New Therapy Prevents Onset of Dravet Syndrome Symptoms in Mice
Technology Networks,
In a development that may finally offer hope to children with Dravet syndrome and their parents, a new promising…
Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model
Jotup,
Data published today in the journal Science Translational Medicine also showed that STK-001 achieved target engagement…
Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model
Stockwatch,
STK-001 has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome A Phase 1/2a…
Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model
Digital Journal,
BEDFORD, Mass.--(Business Wire)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to…
Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model
DMN Newswire!,
STK-001 has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome A Phase 1/2a…
STOKE THERAPEUTICS : Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model
MarketScreener,
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic…
Investigational new therapy prevents onset of Dravet syndrome symptoms in mice
MedicalXpress,
Illustration for Stoke's proprietary TANGO platform and ASOs. Credit: Provided with permission from Stoke Therapeutics In a…
Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model
Business Wire,
STK-001 has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome A Phase 1/2a…
Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model
Morning Star,
STK-001 has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome A Phase 1/2a…
Investigational new therapy prevents onset of Dravet syndrome symptoms in mice
EurekAlert!,
In a development that may finally offer hope to children with Dravet syndrome and their parents, a promising investigational…